Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult men and women~2. Age: 25 to 55 years with documented chronic hepatitis~3. Elevated serum alanine aminotransferase at least 2 times the upper limit of normal (40 U/L) on 2 occasions during the preceding 6 months~4. Detectable anti-HCV antibody status assessed by second-generation enzyme-linked immunosorbent assay (Roche Diagnostics, Branchburg, New Jersey); 5. Detectable HCV RNA by polymerase chain reaction (Cobas Amplicor HCV Monitor v2.0 \[Roche Diagnostics, Branchburg, New Jersey\]; lower limit of quantitation \[50 IU/mL\])~5. Infection with HCV genotype 4~6. Histologic evidence of chronic hepatitis C in a liver biopsy specimen obtained within the preceding year.~Exclusion Criteria:~1. Hepatitis A, hepatitis B, autoimmune hepatitis, alcoholic liver disease, drug-induced hepatitis.~2. Decompensated liver disease with a history of variceal hemorrhage, ascites, or hepatic encephalopathy.~3. Patients coinfected with schistosomiasis or human immunodeficiency virus~4. leukocyte count lower than 3000 /mm3, neutropenia (\<1500 cells/mm3), a hemoglobin level lower than 12 g/dL for women and lower than 13 g/dL for men, thrombocytopenia (\<90,000 cells/mm3), creatinine concentration 1.5 times the upper limit of normal~5. Organ transplantation~6. Neoplastic disease~7. Severe cardiac or pulmonary disease~8. Unstable thyroid dysfunction~9. Psychiatric disorder~10. Current pregnancy or breast feeding.~11. Therapy with immunomodulatory agents within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pegylated interferon alpha 2a plus ribavirin
- 2 (Type: ACTIVE_COMPARATOR): Pegylated interferon alpha 2b plus ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).